Sigyn Therapeutics ( (SIGY) ) has released a notification of late filing.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Sigyn Therapeutics, Inc. has filed a Form 12b-25 to notify investors of a delayed Form 10-K (Yearly Report) for the financial year ended December 31, 2025. The company also notes timing issues tied to preparing information typically included in a Form 10-Q (Quarter Report), underscoring pressure on its financial reporting process.
Management cites that compiling, distributing, and reviewing the required disclosure has proven too time‑consuming to meet the original SEC deadline without causing unreasonable effort and expense. There is no indication of auditor disputes, governance investigations, or internal control restatements driving this delay.
Sigyn Therapeutics expects to file the outstanding Form 10-K (Yearly Report) within the 15‑day extension window allowed under SEC rules. For the quarterly information referenced, the company commits to submitting the related Form 10-Q (Quarter Report) no later than five calendar days after its original due date.
The company states that it does not anticipate any significant change in results of operations compared with the same period of the prior year once the delayed report is filed. As with all such notifications, investors should treat these expectations as forward‑looking statements that may change as the financials are finalized.
Sigyn Therapeutics indicates that all other required periodic filings over the past 12 months have been submitted on time, signaling ongoing baseline compliance with SEC obligations. The notification is signed by Chief Executive Officer James Joyce on March 31, 2026, affirming management’s responsibility for timely remediation of the filing delay.
Spark’s Take on SIGY Stock
According to Spark, TipRanks’ AI Analyst, SIGY is a Underperform.
The overall score reflects significant financial challenges, including persistent net losses, high leverage, and no revenue growth. Technical indicators show mixed signals, with potential short-term upward momentum but risk of being overbought. The valuation is concerning with a negative P/E ratio, suggesting the stock is not a value play. The lack of clear communication in the earnings call adds to the uncertainty. Overall, the stock presents high risk with limited visibility into future improvements.
To see Spark’s full report on SIGY stock, click here.
More about Sigyn Therapeutics
Average Trading Volume: 156,674
Technical Sentiment Signal: Sell
Current Market Cap: $48.16K
For a thorough assessment of SIGY stock, go to TipRanks’ Stock Analysis page.